Paul Tebbey
Chief Operating Officer at Elusys Therapeutics, Inc.
Profile
Paul W.
Tebbey is currently the Director at Radyus Research, Inc. and the Chief Operating Officer at Elusys Therapeutics, Inc. Previously, he held the position of Senior VP-Product Development & Portfolio Strategy at Scorpius Holdings, Inc. from 2021 to 2023.
He holds a doctorate degree from East Carolina University and an MBA from Rochester Institute of Technology.
Paul Tebbey active positions
| Companies | Position | Start |
|---|---|---|
Radyus Research, Inc.
 Radyus Research, Inc. Medical/Nursing ServicesHealth Services Radyus Research, Inc. provides healthcare services. The company is headquartered in Atlanta, GA. | Director/Board Member | - |
Elusys Therapeutics, Inc.
 Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Chief Operating Officer | - |
Former positions of Paul Tebbey
| Companies | Position | End |
|---|---|---|
| SCORPIUS HOLDINGS, INC. | Corporate Officer/Principal | 2022-12-31 |
Training of Paul Tebbey
| East Carolina University | Doctorate Degree |
| Rochester Institute of Technology | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SCORPIUS HOLDINGS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Radyus Research, Inc.
Radyus Research, Inc. Medical/Nursing ServicesHealth Services Radyus Research, Inc. provides healthcare services. The company is headquartered in Atlanta, GA. | Health Services |
Elusys Therapeutics, Inc.
Elusys Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Elusys Therapeutics, Inc. develops antibody therapies. It is engaged in development Anthim (oblitoxaximab) a mAb anthrax antitoxin for the treatment and prevention of inhalational anthrax used in a bioterror attack. The company was founded in May 1998 and is headquartered in Pine Brook, NJ. | Health Technology |
- Stock Market
- Insiders
- Paul Tebbey
